Back to search

Article

CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteins

2026-04-22

Abstract excerpt

CDK4/6 inhibitors are standard-of-care for metastatic estrogen receptor-positive (ER+) breast cancer, yet the development of resistance remains a significant clinical hurdle. While CDK4/6 inhibitors are primarily recognized for their ability to induce cytostasis, their role in modulating innate immune responses remains poorly defined. Here, we demonstrated that CDK4/6i treatment remodels the tumor cell surface to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
19435e1d-cc40-524f-b202-e6198c576fbf
DOI
10.64898/2026.04.19.719504
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CDK4/6 inhibition sensitizes breast cancer to NK cell therapy by inducing immune-interactive surface proteinsDOI 10.64898/2026.04.19.719504
Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapySemantic proximity
Longitudinal and multimodal auditing of tumor adaptation to CDK4/6 inhibitors in HR+ metastatic breast cancersSemantic proximity
Unraveling the breast cancer tumor microenvironment: crucial factors influencing natural killer cell function and therapeutic strategiesSemantic proximity
Differential Expression and Prognostic Significance of CDK1 and CDK6 in Breast Cancer: A Multi-Omics ApproachSemantic proximity
Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.Semantic proximity
Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapySemantic proximity
EphB4 Inhibition Regulates Tumor Microenvironment by Promoting Immunogenic Cell Death Effector Mechanism in Breast CancerSemantic proximity
HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast CancerSemantic proximity
Leveraging NKG2D Ligands in Immuno-OncologySemantic proximity
Immune Gene Signature as a Predictor of CDK4/6 Inhibitor Response in HR+/HER2– Breast CancerSemantic proximity
The regulatory role of CDK4/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (Review)Semantic proximity
Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN signalingSemantic proximity
Select a neighboring publication to make it the new centre.